W

WuXi XDC Cayman Inc
HKEX:2268

Watchlist Manager
WuXi XDC Cayman Inc
HKEX:2268
Watchlist
Price: 31.7 HKD Market Closed
Market Cap: 38B HKD
Have any thoughts about
WuXi XDC Cayman Inc?
Write Note

Gross Margin
WuXi XDC Cayman Inc

31%
Current
29%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
31%
=
Gross Profit
865.5m
/
Revenue
2.8B

Gross Margin Across Competitors

Country CN
Market Cap 38B HKD
Gross Margin
31%
Country US
Market Cap 1.2T USD
Gross Margin
55%
Country US
Market Cap 202.3B USD
Gross Margin
41%
Country US
Market Cap 166.6B USD
Gross Margin
60%
Country KR
Market Cap 66.8T KRW
Gross Margin
49%
Country CH
Market Cap 38.4B CHF
Gross Margin
29%
Country US
Market Cap 38.8B USD
Gross Margin
55%
Country US
Market Cap 36.3B USD
Gross Margin
35%
Country US
Market Cap 27B USD
Gross Margin
59%
Country US
Market Cap 24.1B USD
Gross Margin
35%
Country CN
Market Cap 162B CNY
Gross Margin
40%
No Stocks Found

WuXi XDC Cayman Inc
Glance View

Market Cap
38B HKD
Industry
Life Sciences Tools & Services

WuXi XDC Cayman Inc. is an intriguing player in the biotechnology field, strategically positioned at the crossroads of innovation and precision. As a distinctive subsidiary under the umbrella of WuXi AppTec, it zeroes in on the burgeoning and highly specialized market of antibody-drug conjugates (ADCs). These ADCs are engineered to deliver chemotherapy drugs directly to cancer cells, offering a synthesis of traditional medicine's effectiveness with the pinpoint accuracy of modern biotechnology. This localized delivery aims to enhance therapeutic outcomes while minimizing adverse effects, a compelling value proposition amid rising consumer demand for more personalized cancer treatments. The company thrives through an integrated business model, presenting a suite of comprehensive services that span the entire ADC development lifecycle. It monetizes its expertise by offering clients a seamless pathway from research and development through to clinical manufacturing. Clients, which range from startup biotech firms to established pharmaceutical giants, engage WuXi XDC not only for its technical prowess but also for its capacity to expedite product pipelines. By managing complex supply chains and providing robust regulatory support, the company enables its clients to reduce time-to-market, ultimately maneuvering the intricate framework of drug development with finesse. Through this strategic approach, WuXi XDC has positioned itself as a critical partner in the ADC landscape, driving innovation and delivering value to both its clientele and stakeholders.

Intrinsic Value
30.3 HKD
Overvaluation 4%
Intrinsic Value
Price
W

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
31%
=
Gross Profit
865.5m
/
Revenue
2.8B
What is the Gross Margin of WuXi XDC Cayman Inc?

Based on WuXi XDC Cayman Inc's most recent financial statements, the company has Gross Margin of 31%.